UCB SA (UCBJY) AI Stock Analysis

• Market Cap: $53.49B
• Dividend Yield: 0.56%
• Average Volume (3M): 2.85K
• Price to Earnings (P/E): 37.1
• Beta (1Y): 0.51
• Revenue Growth: 26.28%
• EPS Growth: 457.14%
• Country: US
• Employees: 9,052
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 2.02
• Shares Outstanding: 389,011,320
• 10 Day Avg. Volume: 1,843
• 30 Day Avg. Volume: 2,850
• PEG Ratio: 0.16
• Price to Book (P/B): 3.62
• Price to Sales (P/S): 5.90
• P/FCF Ratio: 39.43
• Enterprise Value/Market Cap: 0.74
• Enterprise Value/Revenue: 5.76
• Enterprise Value/Gross Profit: 7.86
• Enterprise Value/Ebitda: 16.97
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 78 Outperform
• Price Target: $162.00 ▲(15.88% Upside)

UCB SA's strong financial performance and positive earnings call are the primary drivers of its high score. The company's robust growth trajectory and successful product launches bolster confidence. However, the high valuation and potential challenges from pricing pressures and currency headwinds slightly temper the overall outlook.

UCB SA Business Overview & Revenue Model

Company Description

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

How the Company Makes Money

UCB generates revenue primarily through the sale of its pharmaceutical products, which are sold to healthcare providers, hospitals, and pharmacies around the world. The company's revenue model is largely driven by its portfolio of proprietary medications, including established therapies and new product launches. Key revenue streams include direct sales of these products, royalties from licensing agreements, and collaborations with other pharmaceutical companies for joint development and marketing of drugs. UCB also engages in research partnerships with academic institutions and other organizations, which can lead to additional funding and resource sharing that bolster its revenue potential. The company's strategic focus on innovation and its commitment to addressing unmet medical needs contribute significantly to its earnings, ensuring a steady flow of income from both existing and new therapies.

UCB SA Financial Statement Overview

Summary

UCB SA demonstrates strong financial performance with significant revenue growth, high profitability margins, and robust cash flow generation. The balance sheet is stable with low leverage, providing a strong foundation for future growth.

Income Statement

UCB SA's income statement reflects strong profitability with a robust gross profit margin of 71.6% and a net profit margin of 17.3% for 2024. The company has demonstrated significant revenue growth of 17.1% year-over-year, indicating a positive growth trajectory. Additionally, the EBIT margin is solid at 21.5%, and the EBITDA margin is impressive at 31.9%, showcasing operational efficiency.

Balance Sheet

The balance sheet of UCB SA is solid, with a debt-to-equity ratio of 0.30, indicating low leverage and strong financial stability. The return on equity stands at 10.6%, reflecting moderate profitability relative to shareholder equity. The equity ratio is healthy at 57.8%, signifying a strong equity base relative to total assets.

Cash Flow

UCB SA shows strong cash flow generation capabilities with a 106.7% growth in free cash flow. The operating cash flow to net income ratio is 1.17, indicating effective conversion of net income to cash. The free cash flow to net income ratio is 0.86, highlighting robust cash flow relative to profit, supporting the company's liquidity and investment capacity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.85B	6.15B	5.25B	5.52B	5.78B	5.35B
Gross Profit	5.03B	4.40B	3.54B	3.84B	4.34B	3.98B
EBITDA	2.33B	1.96B	1.28B	1.17B	1.59B	1.30B
Net Income	1.33B	1.06B	343.00M	418.00M	1.06B	732.00M
Balance Sheet
Total Assets	17.19B	17.35B	15.54B	15.87B	14.21B	13.32B
Cash, Cash Equivalents and Short-Term Investments	2.01B	1.76B	923.00M	1.14B	1.48B	1.52B
Total Debt	2.88B	3.03B	3.04B	2.90B	2.12B	2.75B
Total Liabilities	7.50B	7.32B	6.56B	6.80B	5.82B	6.05B
Stockholders Equity	9.68B	10.03B	8.97B	9.06B	8.39B	7.27B
Cash Flow
Free Cash Flow	1.25B	920.00M	445.00M	748.00M	1.06B	732.00M
Operating Cash Flow	1.58B	1.24B	761.00M	1.12B	1.55B	1.08B
Investing Cash Flow	286.00M	282.00M	-440.00M	-1.58B	-487.00M	-2.23B
Financing Cash Flow	-691.00M	-818.00M	-308.00M	70.00M	-1.12B	1.18B

UCB SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 139.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UCBJY, the sentiment is Positive. The current price of 139.8 is below the 20-day moving average (MA) of 146.25, above the 50-day MA of 129.88, and above the 200-day MA of 103.50, indicating a neutral trend. The MACD of 3.92 indicates Positive momentum. The RSI at 50.38 is Neutral, neither overbought nor oversold. The STOCH value of 3.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UCBJY.

UCB SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UCBJY	―	$53.49B	37.14	13.80%	0.56%	26.28%	457.14%
ARGX	―	$50.39B	38.98	24.75%	―	89.58%	―
RPRX	―	$21.73B	16.22	15.92%	2.33%	3.04%	53.03%
REGN	―	$61.26B	14.56	15.34%	0.45%	5.38%	3.58%
ALNY	―	$60.75B	―	-257.82%	―	5.01%	-330.09%
BNTX	―	$25.40B	―	-1.81%	―	7.51%	30.53%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

UCB SA Corporate Events

UCB S.A. Reports Strong Growth and Positive Outlook in 2025 Earnings Call

UCB S.A. Reports Strong First Half of 2025 Amid Revenue Growth and Positive Outlook

UCB S.A. Reports Strong Growth and Positive Outlook

UCB S.A. is a global biopharmaceutical company headquartered in Brussels, Belgium, focusing on innovative treatments for severe diseases of the immune and central nervous systems.